Pomerantz Law Firm Warns Investors of Class Action Against ARS Pharmaceuticals: Key Details to Know

Investor Alert: ARS Pharmaceuticals Class Action Lawsuit

On September 10, 2026, Pomerantz LLP announced the initiation of a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). This legal action stems from concerns about possible securities fraud or unlawful business practices within the company. Investors who suffered losses while investing in ARS are urged to respond as the deadline to act is fast approaching.

The lawsuit has been triggered primarily due to claims that ARS and certain executives may have misled investors regarding the company's insurance coverage for their key product, Neffy, an epinephrine nasal spray. On June 24, 2026, ARS disclosed that it did not receive expanded insurance coverage through CVS Caremark by the anticipated deadline of July 1, 2026. This announcement led to a significant drop in the company’s stock price, plummeting by 23.91% on June 25, 2026, to close at $8.02 per share. Investors who purchased ARS securities during the specified Class Period have until October 5, 2026, to ask the Court to appoint them as Lead Plaintiffs for this class action.

For investors looking to join this class action, it is imperative to contact Danielle Peyton at Pomerantz LLP. Interested parties can reach her via phone at 646-581-9980 or toll-free at 888-4-POMLAW, Ext. 7980. Emails should include a mailing address, phone number, and the number of shares purchased to facilitate the joining process. A copy of the complaint can also be obtained from the firm's website at www.pomerantzlaw.com.

Background on ARS Pharmaceuticals

ARS Pharmaceuticals focuses on providing innovative treatments for severe allergic reactions. Their product, Neffy, is touted for ease of use in emergency settings. However, the lack of insurance coverage for such a crucial product has raised alarms among investors. The delay in CVS's decision regarding expanded coverage—which is now expected until January 2027—has complicated ARS’s growth and market strategies, especially with the approaching allergy seasons.

Role of Pomerantz Law Firm

Founded by the influential figure Abraham L. Pomerantz, the firm is recognized for its pioneering work in securities class actions, with more than 85 years of fighting for investor rights. Pomerantz LLP has successfully recovered multimillion-dollar damages for investors impacted by corporate misconduct and securities fraud. The firm maintains a strong presence in various cities, including New York, Chicago, and London, emphasizing its commitment to defending the rights of affected parties.

Looking Ahead

For those who believe they have been significantly impacted by the activities of ARS Pharmaceuticals, the upcoming deadline poses a critical opportunity to seek legal recourse. Failure to act by October 5, 2026, may leave potential claimants unable to recover losses incurred during the class period.

In summary, ARS Pharmaceuticals is currently facing serious legal challenges as articulated by Pomerantz Law Firm, making it vital for affected investors to consider their legal options promptly. By joining this class action, they can seek justice and potentially recover their investments lost due to alleged corporate malpractice.

Stay informed and proactive if you have stakes in ARS Pharmaceuticals. For assistance, reach out to Pomerantz to discuss joining the suit before the crucial deadline.